Full Press Release Details
NovaBay Pharmaceuticals APPOINTS MARK M. SIECZKAREK, SOLTA MEDICAL CHAIRMAN AND CEO AND DR. MASSIMO RADAELLI, NOVENTIA PHARMA CEO TO ITS BOARD OF DIRECTORS
Combined total of over 50 Years of Healthcare Experience in Global Markets Adds Significant Depth to NovaBay's Board
EMERYVILLE, CA - January 9, 2014 - NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, has appointed Mark M. Sieczkarek and Dr. Massimo Radaelli to its Board of Directors.
Dr. Ron Najafi, NovaBay Chairman and Chief Executive Officer, said: "We are honored to welcome Mark and Massimo to the NovaBay Board of Directors and look forward to working with them to continue building shareholder value. Their expertise in commercialization, orphan diseases, and global product registration will prove invaluable as we move toward further commercial and clinical development of NovaBay."
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its Aganocide compounds, led by auriclosene. Auriclosene is a new chemical entity invented by NovaBay that has a broad spectrum of activity against bacteria, viruses and fungi. Aganocide compounds are based on the human body's natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in published studies. Once pathogens penetrate the body's primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. NovaBay believes that Aganocides will help reduce the rise of antibiotic resistance as they begin to supplant the usage of classic topical antibiotics.
Forward-looking Statements
This release contains forward-looking statements and opinions, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding building shareholder value and the effect that Aganocides may have. The words "look forward," "unlikely," "believe" and "will" are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay's progress:
Connect with NovaBay on LinkedIn
Visit NovaBay's Website
NovaBay Pharmaceuticals Contacts
Chief Financial Officer
Director, Investor Relations and Corporate Communications
NovaBay Pharmaceuticals, Inc.